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PENGGUNAAN SISTEM PENGEMULSIAN KENDIRI NOVEL BAGI SATU DRUG 
UPOFILIK BERBIOKEPEROLEHAN RENDAH 
ABSTRAK 
Kajian ini dijalankan untuk membangunkan satu sediaan sistem pengemulsian kendiri 
(SES) untuk meningkatkan penyerapan sistemik drug yang berbiokeperolehan rendah 
dengan menggunakan ubiquinone sebagai drug model. Satu kaedah kromatografi 
cecair prestasi tinggi yang mudah, dan mempunyai spesifisiti, ketepatan dan kejituan 
yang diperlukan telah dibangunkan untuk menentukan kepekatan ubiquinone dalam 
plasma tikus dan manusia. 
Beberapa aspek yang membawa kepada perumusan SES yang sesuai telah dikaji. lni 
termasuk, penentuan kelarutan ubiquinone dalam lemak (log p oktanollakueus). penilaian 
beberapa jenis larutan pengangkut yang berpotensi dan kepekatan agen aktif 
permukaan, kecekapan untuk mengemulsi secara kendiri, penilaian saiz titisan yang 
terbentuk dari pelbagai gabungan larutan pengangkut dan agen permukaan dan akhir 
sekali, penilaian muatan drug dan kestabilan kimia ubiquinone dalam sediaan-sediaan 
pengemulsian kendiri (SE). Daripada kajian-kajian ini, sediaan SE optima yang 
mengandungi campuran asid a-linolenik dan Cremophor® EL pad~ nisbah 9:1 w/w 
serta dimuatkan dengan 60 mg/g ubiquinone didapati mempunyai prestasi in vitro yang 
paling memuaskan. 
Dalam satu kajian in vivo yang melibatkan penggunaan tikus Sprague-Dawley, 
biokeperolehan oral ubiquinone yang diperolehi daripada sediaan SE optima didapati 
setanding dengan yang dihasilkan oleh sediaan pengemulsian mikro kendiri (SME) 
ubiquinone, Q-Gel® Forte yang boleh diperolehi secara komersial. Satu lagi kajian in 
vivo telah dijalankan menggunakan sukarelawan manusia yang sihat, di mana prestasi 
xxi 
in vivo sediaan SE yang optima dibandingkan dengan Q-Gel® Forte serta satu sediaan 
ubiquinone dalam bentuk ampaian berlemak, Bio-Quinone yang juga boleh didapati di 
pasaran. Tahap biokeperolehan ubiquinone yang dicapai oleh sediaan SE optima 
didapati meningkat (walaupun tidak mempunyai perbezaan yang signifikan secara 
statistik) jika dibandingkan dengan Q-Gel® Forte, manakala kedua-dua sediaan ini 
menghasilkan tahap biokeperolehan ubiquinone yang lebih tinggi ... secara signifikan 
(p<0.05) jika dibandingkan dengan sediaan ampaian berlemak, Bio-Quinone. 
Sebagai kesimpulan, sediaan SE optima yang terdiri daripada campuran asid a-
linolenik dan Cremophor® EL pad a nisbah 9:1 w/w, dapat mengemulsi secara kendiri 
dengan memuaskan dan juga dapat meningkatkan biokeperolehan oral drug lipofilik 
seperti ubiquinone. 
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UTILITY OF A NOVEL SELF-EMULSIFYING SYSTEM FOR A LIPOPHILIC DRUG 
WITH LOW ORAL BIOAVAILABILITY 
ABSTRACT 
The present study was conducted to formulate a self-emulsifying system (SES) for 
enhancing the systemic absorption of poorly bioavailable lipophilic drugs, using 
ubiquinone as the model drug. A simple high performance liquid chromatographic 
method with the required specificity, precision and accuracy was first developed for 
quantification of ubiquinone in rat and human plasma. 
Several aspects leading to the formulation of a suitable SES for ubiquinone were first 
studied. They included the determination of the ubiquinone lipid solubility (log 
P octanoltaqueous), evaluation of various potential oily vehicles, type and concentrations of 
surfactants, the self-emulsification efficiency and emulsion droplet sizes of various 
surfactant and vehicle combinations and finally the drug loading and chemical stability 
of ubiquinone in the self-emulsifying (SE) formulations. From these studies, an 
optimised SE formulation comprising a 9:1 w/w mixture of a-linolenic acid and 
Cremophor® EL loaded with 60 mg/g of ubiquinone was found to have the most 
satisfactory in vitro performance. 
An in vivo study conducted using Sprague-Dawley rats revealed that the oral 
bioavailability of the optimised SE formulation was comparable to that of a 
commercially available self-microemulsifying (SME) ubiquinone formulation, Q-Gel® 
Forte. Another in vivo study was also carried out using healthy human volunteers, 
comparing the optimised SE formulation to Q-Gel® Forte as well as another 
commercially available oily suspension of ubiquinone, Bio-Quinone. It was found that 
xxiii 
the extent of bioavailability of the optimised SE formulation was slightly higher 
(although not statistically significant) than that of Q-Gel® Forte and both were 
significantly (p<0.05) higher than the oily drug suspension, Bio-Quinone. 
In conclusion, the optimised SE formulation comprising a 9:1 w/w mixture of a-linolenic 
acid and Cremophor® EL could self-emulsify satisfactorily and also enhance the oral 
bioavailability of lipophilic drugs such as ubiquinone. 
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CHAPTER 1 INTRODUCTION 
1.1 GENERAL PRINCIPLES OF ORAL BIOAVAILABILITY 
Due to ease and convenience, the oral route remains by far the most common 
and preferred mode of drug administration (Gudzinowicz and Gudzinowicz, 
1984; Shargel and Yu, 1999). However, not all drugs are well absorbed orally 
and their bioavailability has always been a major concern during development 
of an oral dosage form. Bioavailability refers to the rate and extent (amount) in 
which a therapeutically active drug reaches the systemic circulation after its 
administration (Shargel and Yu, 1999). Upon oral administration, a drug must 
be released from its dosage form to be dissolved in the gastrointestinal fluids. 
The dissolved form will then have to pass through the gastrointestinal barrier in 
order to gain access into the systemic circulation. A vast majority of orally 
administered drugs is absorbed from the mesenteric-branched arterioles and 
channelled through the hepatic portal vein leading to the liver prior to reaching 
the systemic circulation. On the other hand, absorption of certain lipophilic 
drugs can also occur via the intestinal lymphatic system, bypassing the hepatic-
portal vein and therefore, the liver. Hence, in order to formulate an oral dosage 
form with satisfactory drug bioavailability, it is essential to understand the 
physicochemical, physiological and formulation factors that can affect the 
systemic absorption of a drug. These factors will be elaborated in the following 
sections. 
1.1.1 PHYSICOCHEMICAL FACTORS 
The physicochemical properties of a drug that can influence its passage into 
solution and transfer across membranes include lipid solubility, chemical 
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stability, particle size and complexation potential (Ashford, 2002). 
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Prior to absorption, a drug has to be present in the dissolved .. form. Factors that 
can affect the dissolution rate are particle size, wettability, solubility and the 
physical form of the drug (either in salt or free form as well as crystalline or 
amorphous form) (Ashford, 2002). 
An increase in the total surface area of drug particles in contact with the 
gastrointestinal fluids results in an increase in the drug dissolution rate. 
Provided that each particle of drug is intimately wetted by the gastrointestinal 
fluids, the effective surface area exhibited by the drug is dir~ctly related to the 
particle size of the drug. For a similar mass of drugs, the smaller the particle, 
the bigger will be the effective surface area (Ashford, 2002). Small particles 
with greater surface area dissolve more rapidly than larger particles even 
though both have the same intrinsic solubility. Nevertheless, particle size 
appears to have less influence on the absorption of drugs with high aqueous 
solubility, but it may have pronounced effect on the absorption of drugs with low 
aqueous solubility (Kwan eta/., 1986). 
As the pH value varies from acidic in the stomach to slightly alkaline in the 
small intestine, the solubility of a drug differs as it travels along the 
gastrointestinal tract. Theoretically, solubility of an acidic drug gradually 
increases as it advances towards the small intestine whereas a basic drug has 
the highest solubility in the stomach. However, in reality, the large intestinal 
surface area compared to that of the stomach as well as the relatively longer 
residence time of the drug in the intestine than in the stomach, facilitate primary 
drug absorption from the small intestine regardless of its acidic or basic nature. 
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Certain drugs have poor solubility in the gastrointestinal fluids and their 
solubility can be increased with the appropriate soluble salt formation. For 
instance, the solubility of the free acid form of naproxen, a non-steroidal anti-
inflammatory drug, is lower than that of the salt form, sodium naproxen 
(Sevelius et a/., 1980). 
Polymorphism occurs when an organic compound has the capability of existing 
in more than one crystal form (Carstensen, 2002). Polymorphs may exhibit 
significantly different physical properties such as solubility, melting point and 
density. Metastable crystals, which possess higher energy, are less stable and 
hence, will be converted to the stable form eventually. Thus, the more stable 
forms are preferable for use in the final dosage form. Meanw~ile, less energy is 
required to dissolve the amorphous form of a drug compared to the crystalline 
form, indicating that the amorphous form is more soluble than the crystalline 
form. 
Lipid solubility of a drug has an impact on the permeation rate of the drug 
through the gastrointestinal barrier. Lipid soluble and non-ionisable drugs with 
high partition coefficients are capable of penetrating a variety of lipidic 
boundaries of the body cells and tissues (Gudzinowicz and Gudzinowicz, 
1984). The lipidic characteristic of a drug depends on· the presence of 
hydrophobic non-polar groups in the molecule. As the number of non-polar 
groups such as an alkyl group increases, the lipidic characteristic becomes 
more pronounced resulting in enhanced lipid solubility. 
~.· 
Drugs with low chemical stability are subjected to hydrolysis and enzymatic 
degradation in the gastrointestinal fluids. Hence, the amount for absorption is 
decreased, leading to reduced bioavailability as exemplified by erythromycin 
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base, which is rapidly destroyed by gastric acid. In order to protect 
erythromycin from degradation, its dosage form is enteric coated. Alternatively, 
it can be administered as a prodrug, namely, erythromycin stearate (Posti and 
Salonen, 1983). 
Complexation of a drug may occur in the gastrointestinal fluids. The complexing 
agent may be a substance naturally present in the gastrointestinal tract, from a 
dietary source or an excipient in the dosage form. The solubility of the 
complexed form of a drug may be different from that of its original form. 
Therefore, complexes with better solubility are able to enhance bioavailability 
while those of poorer solubility will reduce drug bioavailability (Ashford, 2002). 
1.1.2 PHYSIOLOGICAL FACTORS 
Biological membranes, being the major structure in cells, function not only to 
enclose the cell contents but also act as selective barriers -to the passage of 
molecules as a result of their lipidic and semipermeable nature. Two important 
pathways are involved in the transportation of drugs across the gastrointestinal 
barriers into the systemic circulation, namely the transcellular and paracellular 
pathways. Transcellular pathway refers to the transportation of drug molecules 
across the cell whereas paracellular pathway involves the movement of drug 
molecules through the gaps or tight junctions between the cells. 
Transcellular absorption is further divided into passive diffusion, carrier-
mediated transport (active transport and facilitated diffusion) and endocytosis. 
Passive diffusion is a process that involves the movement of drugs across a 
concentration gradient between the gastrointestinal tract and the systemic 
circulation with no assistance from external energy (Notari, 1987; Shargel and 
Yu, 1999). It is the preferre~ route of transport for relatively small molecules 
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and thus many drugs are transported via passive diffusion. On the other hand, 
certain compounds and many nutrients are absorbed transcellularly by a 
carrier-mediated transport mechanism of which there are two main types, active 
transport and facilitated diffusion. Active transport involves the delivery of a 
drug across the cell membrane against the concentration gradient with the 
assistance of a carrier. In contrast, facilitated diffusion requires a concentration 
gradient as the driving force because, unlike active transport, this mechanism 
cannot transport drug against the concentration gradient. Transportation of 
substance by this mechanism is at a much faster rate than would be anticipated 
for a normal diffusion process based on the molecular size and the polarity of 
the molecule. Endocytosis can be described as the engulfment of 
macromolecules by the cell membrane and subsequent transportation of the 
entire molecule into the cell (Ashford, 2002). 
Present in the membranes of the enterocytes lining the gastrointestinal tract are 
certain counter transport efflux proteins, particularly P-glycoprotein (P-gp). 
These counter transporters can limit drug bioavailability by transporting the 
absorbed drugs back into the gastrointestinal lumen. ·In addition, the 
enterocytes also contain drug-metabolising enzymes, especially CYP3A4, 
which belongs to a subfamily of cytochrome P450. Being co-localised in the 
enterocytes of gastrointestinal tract, P-gp and CYP 3A4 are capable of working 
synergistically, as both have overlapping substrate activity (Watkins, 1 997). 
Other physiological factors that can affect oral bioavailability include gastric 
emptying rate, gastrointestinal motility as well as food status and food - drug 
interactions. 
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1.1.3 FORMULATION FACTORS 
Various dosage forms have been used to administer drugs orally and their 
bioavailabilities differ from one another. Drug administered orally as a solution is 
absorbed faster than that in the form of a tablet or capsule. On the other hand, 
sustained-release dosage forms are devised to release their drug contents over an 
extended period of time, thereby providing a slow and sustained rate of absorption 
compared to conventional immediate-release dosage forms (Shargel and Yu, 
1999). 
Additionally, excipients used in the formulation of pharmaceutical dosage forms 
may also affect the bioavailability of a drug. For instance, magf!esium stearate, a 
lubricant, is lipophilic and has water repellent characteristic. Its hydrophobic nature 
hinders liquid penetration into the tablet or capsule formulation and hence can 
impede the disintegration and dissolution of the drug in the gastrointestinal fluids. 
Surfactants, on the other hand, are able to increase the wettability of certain 
lipophilic drugs resulting in an increase in the rate of disintegration and dissolution, 
leading to improved oral bioavailability (Shargel and Yu, 1999). 
1.2 LIPIDS AS DRUG DELIVERY CARRIERS 
The ability of lipids to solubilise lipophilic drugs within the matrices of dosage forms 
often results in improved drug bioavailability, due to increased aqueous solubility 
and dissolution rate of drugs in the gastrointestinal fluids (Wasan, 2001). According 
to Humberstone and Charman (1997), lipid formulations can reduce the inherent 
limitations of slow and incomplete dissolution of poorly water-soluble drugs through 
the formation of solubilised phases from which absorption may occur. 
Lipids offer versatility in oral drug administration as they can be formulated as 
solutions, suspensions, emulsions, self-emulsifying systems and 
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microemulsions. The availability of unit dosage forms such as soft or sealed 
hard gelatin capsules not only makes lipid formulations feasible but also 
practical and aesthetically acceptable to consumers. 
1.3 LIPID SOLUTION AND SUSPENSION 
The increased bioavailability of poorly soluble drugs with co-administration of 
food has prompted the investigation of using digestive lipids to dissolve or 
suspend this class of drugs for enhancing bioavailability. It has been shown that 
the bioavailability of corn oil suspensions of griseofulvin (Carrigan and Bates, 
1973) and phenytoin (Chakrabakti and Belpaire, 1978) was 200% and 150% 
compared to that of an aqueous suspension of the respective drugs. In a study 
carried out by Abrams et a/. (1978) comparing the bioavailability of a lipid-
based solution of a lipophilic steroid derivative and an aqueous suspension, it 
was found that the bioavailability of the lipid-based solution was three-fold 
higher than that of the aqueous suspension. Besides that, lipid based 
formulations of a lipophilic anti-malarial amine (Stella et a/., 1978), cinnarizine 
(Tokumura et a/., 1987) and progesterone (Hargrove et al., 1989) also showed 
improved bioavailability compared to their respective capsule, tablet and 
powdered formulations. 
1.4 SELF-EMULSIFYING DRUG DELIVERY SYSTEM (SEDDS) 
1.4.1 INTRODUCTION 
Pouton (1985 and 1997) defined a self-emulsifying drug. delivery system 
(SEDDS) as an isotropic mixture of oil and surfactant (sometimes with added 
cosurfactant) that forms emulsion upon aqueous dilution with little or no energy 
input. It represents an efficient vehicle for the in vivo administration of 
emulsions (Constatinides, 1995). The mixture, either in the form of solution or 
suspension, can be encapsulated in soft or hard gelatin capsules. After oral 
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administration, the content of the capsule will be liberated from the capsule 
shell. Upon contact with the gastrointestinal fluids, the self-emulsifying 
formulation spreads readily in the gastrointestinal tract and self-emulsification 
will be initiated by the gentle agitation provided by digestive motility of the 
stomach and the small intestine (Shah eta!., 1994). In a recent review by Craig 
eta/. (2000), the formulation of SEDDS is relatively simple in theory, as it only 
requires the incorporation of the drug into a suitable oil-surfactant mixture. A 
comprehensive review on SEDDS has also been published by Gursoy and 
Benita (2004). 
1.4.2 FORMULATION 
While self-emulsification has been shown to be dependent on the nature of 
oil/surfactant mixture, surfactant concentration and oil/surfactant ratio as well as 
temperature at which self-emulsification occurs (Pouton, 1985; Wakerly eta/., 
1986; Wakerly et a/., 1987), the oily vehicle used is also an important 
determinant for a successful formulation of SEDDS. Besides solubilising 
lipophilic drugs and facilitating self-emulsification, the oily vehicle can also 
promote transport of lipophilic drugs via the lymphatic system, hence helping to 
increase oral bioavailability (Charman and Stella, 1991; Lindmark eta/., 1995; 
Gershanik and Benita, 2000; Holm et a/., 2002). Several long- and medium-
chain glycerides have been used as vehicles or model systems according to a 
review by Constatinides (1995). It has been suggested that medium-chain 
triglycerides are more preferable compared to long-chain triglycerides in the 
formulation of SEDDS due to their better solvent capacity as well as ease of 
self-emulsification. To date, except for the data reported by Mulye (2000) and 
Ng (2005), no other data on SEDDS using fatty acids as the oily vehicles has 
been published. Fatty acids have been used by Kajita et a/. (2000) for the 
preparation of an emulsion to improve mucosal absorption of vancomycin 
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hydrochloride in rats. Oleic acid, a monounsaturated fatty acid has been used 
in the formulation of a nonself-emulsifying product of testosterone 
undecanoate, Andriol® (Organon, NJ, USA). 
As surfactant molecules contain both polar and non-polar groups, they tend to 
adsorb at the interfaces between the oil and aqueous phases with the 
hydrophilic group located in the aqueous phase while the lipophilic group in the 
oil phase (Salager, 2000). Non-ionic surfactants are often preferred in 
pharmaceutical formulations, especially oral preparations as these compounds 
are generally less toxic and safer than the ionic surfactants. Moreover, being 
non-ionic in nature, the activity of these surfactants is less influenced by 
changes in pH and ionic strength (Constatinides and Scalart, 1995). An 
important property of these surfactants concerning the bioavailability of drugs is 
that they can cause moderate reversible changes in the permeability of the 
intestinal wall (Wakerly eta/., 1986). The hydrophile-lipophile balance (HLB) of 
surfactants has been used in their selection for formulating SED OS (Eccleston, 
1992; Atwood, 1994). Surfactants with HLB values ranging from 3 to 8 are 
usually used for formulating water-in-oil emulsions whereas those of HLB 
values in the range of 8 to18 are applied in oil-in-water emulsions (Osborne et 
a/., 1988; Constatinides and Scalart, 1995). 
Apart from surfactants, cosolvents such as ethanol, propylene glycol, 
polyethylene glycols and glycerol are occasionally incorporated into a SEDDS 
in order to increase the solvent capacity. Vonderscher and Meinzer (1994) have 
substantiated the addition of cosolvents to produce very fine dispersion under 
gentle agitations (Constantinides, 1995; Constantinides and Scalart, 1995) in 
their formulation of a SE preparation of cyclosporine A. 
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1.4.3 MECHANISM OF SELF-EMULSIFICATION 
According to Constantinides (1995), spontaneous emulsification of SEDDS 
occurs because the free energy required for emulsification is low and could be 
either positive or negative. As the oil/surfactant mixture is diluted with water, a 
liquid crystalline phase is formed between the oil/surfactant and water phases. 
The effective swelling of this liquid crystalline phase allows spontaneous 
formation of an interface between the oil droplets and the water (Groves and 
Galindez, 1976; Wakerly eta/., 1986). The other possible mechanism proposed 
by these researchers was the rapid infiltration of water into the liquid crystalline 
phase resulting from gentle agitation instigates interface disruption and droplet 
formation. The presence of liquid crystalline phase surrounding the oil droplets 
gives rise to a stable self-emulsified system that prevents coalescence of the oil 
droplets. 
Several studies to determine the involvement of liquid crystalline phase in the 
emulsification process have been carried out by Wakerly et at. (1986), Wakerly 
et a/. (1987), Pouton et a/. (1987), Craig et a/. (1993) and Craig et at. (1995). 
According to Craig et at. (1993), the formation of the liquid crystalline phase 
was assumed to be largely dependent on the ratio of oil to surfactant and to 
water, which in turn accounted for the high specificity of the proportions of oil 
and surfactant required for self-emulsification as suggested by Pouton (1985). 
In addition, the drug in the formulation may alter the emulsion characteristics, 
probably by interacting with the liquid crystalline phase (Craig_ eta/., 1993). The 
complex relationship between the formation of liquid crystalline and 
emulsification was further substantiated by Craig et a/. (1995) through 
examining a series of lmwitor 742 (a mixture of mono- and diglycerides of 
capric and caprylic acids) and Tween 80 systems using particle size analysis 
and low frequency dielectric spectroscopy. 
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1.4.4 DRUG ABSORPTION FROM SEDDS 
Craig et a/. (2000) has identified two differences in the drug uptake between a 
SEDDS and an ingested oily liquid. First, in SEDDS, oil is presented to the 
gastrointestinal tract in fine droplets, thus increasing the surface area for 
absorption instead of a single continuous phase. Second, the presence of 
emulsifying agents in the SEDDS facilitates emulsification, leading to better 
absorption. Charman et a/. (1992) carried out a formulation and 
biopharmaceutic study on a lipophilic anti-viral compound, WIN 54954, in which 
the bioavailability of this compound in SEDDS was compared with that of a 
PEG 600 formulation. Although no significant difference was observed between 
the mean bioavailability of the two formulations, greater reproducibility was 
obtained with the SEDDS. Shah et a/. (1994) also reported that the 
bioavailability of Ro-150778, a highly lipophilic naphthalene derivative, obtained 
with a SEDDS was four-fold and twenty-fold higher than that of a PEG 400 
solution and a standard tablet preparation of the compound respectively. The 
improved bioavailability of drugs administered in the form of a SEDDS 
compared to a normal oily solution was further detailed by Humberstone and 
Charman (1997). More recently, Ja and Young (2000) showed that the oral 
bioavailability of indomethacin (a poorly water-soluble drug) in rats was 
increased by 57% when administered in the form of SEDDS compared to that 
of a methylcellulose suspension. 
1.5 SELF-MICROEMULSIFYING DRUG DELIVERY SYSTEM 
Self-microemulsifying drug delivery system (SMEDDS) is a SEDDS which 
forms transparent microemulsion with droplet sizes of less than 50 nm. 
Improved oral bioavailability as a result of the formation of._nanosize droplets 
was demonstrated by the improved version of cyclosporine A formulation, 
Sandimmune Neoral compared to the older formulation, Sandimmune (Holt et 
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a/., 1994). The former, which could produce a microemulsion, showed 1.3 to 
1.5 times higher in the extent of systemic absorption compared to the latter, 
which could only yield a crude emulsion. Often, cosurfactants and/or cosolvents 
are utilised instead of a single surfactant system in order to obtain emulsions 
with very fine droplet sizes. Moreover, the amount of surfactant used is 
normally higher than that used in the formulation of a normal SEDDS (Karim et 
a/., 1994; Vondercher and Meinzer, 1994; Constantinides, 1995; Meinzer eta/., 
1995). 
1.6 UBIQUINONE 
1.6.1 INTRODUCTION 
Ubiquinone is also known as coenzyme Q10, coenzyme Q(50), ubidecarenone 
and mitoquinone. It was first isolated from the mitochondria of beef heart by 
Crane et a/. (1957) in USA. In 1958, Dr. Karl Folkers and his co-workers 
elucidated the molecular structure of the compound to be 2,3 dimethoxy-5-
methyl-6-decaprenyl benzoquinone (Sinatra, 2005) as shown in Figure 1.1, with 
a molecular weight of 863.37. It has a melting point of 48°C. At room 
temperature, ubiquinone appears as a yellow to orange crystalline powder. It is 
practically insoluble in water, soluble in acetone and very slightly soluble in 
ethanol. It gradually decomposes and darkens upon exposure to light (British 
Pharmacopeia, 2003). 
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Fig. 1.1 : Structural formula of ubiquinone 
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Ubiquinone is basically a vitamin or vitamin-like substance found naturally in 
every cell of the body as it is synthesised in all the tissues in the body. 
Relatively high concentrations of ubiquinone are found in the heart, liver, kidney 
and pancreas (Linnet a/., 1959). Although ubiquinone is also present in a wide 
variety of food, daily dietary intake of approximately 2-5 mg is insufficient to 
produce any substantial clinical benefits (Sinatra, 2005). 
1.6.2 THERAPEUTIC BENEFITS OF UBIQUINONE 
About 40 to 50% of ubiquinone is concentrated in the mitochondria of a cell. It 
is the coenzyme for at least three mitochondrial enzymes, which are crucial in 
the production of adenosine triphosphate (ATP), required for cellular functions, 
as well as the enzymes in other parts of the cell (Langsjoen, 1994). Besides 
being involved in the production of ATP, ubiquinone also functions as a potent 
antioxidant and a membrane stabiliser. Due to its pivotal role in ATP production 
and antioxidant activity, ubiquinone thus exhibits many therapeutic benefits. 
The findings by Folkers et at. (1970), Littarru et at. (1972a and 1972b), Folkers 
et a/. (1985) and Frustaci et a/. (1985) that heart tissues are generally deficient 
in ubiquinone when patients suffer from heart diseases, have prompted 
extensive investigations to evaluate the benefits of ubiquinone in treating heart 
diseases. There were at least nine placebo-controlled studies documented, all 
confirming the effectiveness and safety of ubiquinone in the treatment of heart 
diseases. Besides that, there were eight international symposia being held from 
1976 to 1993 uncovering the biomedical and clinical aspects of ubiquinone via 
more than 300 presentations by scientists and physicians from 18 countries 
(Langsjoen, 1994). The majority of these studies related to the treatment of 
heart diseases showed that ubiquinone significantly improved heart muscle 
function with no obvious adverse effects. 
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Apart form treating heart diseases, studies on the benefits of ubiquinone as a 
supplement to reduce hypertension have also been carried out. Yamagami et 
a/. (1976) reported a reduction in systolic and diastolic pressure in selected 
patients upon repleting their ubiquinone deficiency. Greenberg and Frishman 
(1990) who conducted a double blind placebo-controlled study involving 20 
hypertensive patients with low serum ubiquinone concentrations, found a 
significant reduction in systolic and diastolic pressure in patients receiving 33.3 
mg of ubiquinone 3 times per day while no improvement was obserVed in the 
placebo group. In an open-label study conducted by Langsjoen et a/. (1994), 
average daily dose of 225 mg ubiquinone for six months in combination with 
standard antihypertensive drug therapy, enabled 51% of the participants to 
discontinue one to three of their antihypertensive medications. In another 
randomised, double blind, placebo-controlled study carried out by Burke et a/. 
(2001), 55% of participants with systolic hypertension, but normal diastolic 
pressure who received 60 mg of ubiquinone per day responded positively after 
a twelve-week period compared to the placebo group. 
The involvement of ubiquinone in oxidative/reductive reactions has rendered it 
a potent antioxidant (Ozawa, 1985; Ernster and Forsmark-Andree, 1993) by 
inhibiting lipid and protein peroxidation as well as scavenging free radicals. The 
reduced form gives up electron readily to neutralise oxidants/radicals. Being a 
powerful antioxidant, ubiquinone has the potential to be an anti-cancer and 
immune-stimulating agent. Studies carried out by Folkers et a/. (1988) and 
Lockwood et a/. (1995) showed that there was primary evidence that 
ubiquinone might help in improving the immune system of HIV/AIDS patients 
and inhibit or reduce the growth of breast cancer cells. In recent years, it has 
also been widely used in skin care products to combat aging despite the 
paucity of scientific evidence. 
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In addition, therapeutic benefits of ubiquinone for combating diseases such as 
dental disease (Wilkinson eta/., 1977), chronic renal failure (Singh eta/., 2000), 
Huntington disease (The Huntington Study Group, 2001 ), Parkinson disease 
(Shults et a/., 2002) and migraines (Rozen et a/., 2002) are still being 
extensively investigated. 
1.6.3 ABSORPTION OF UBIQUINONE 
As mentioned under Section 1.6.1, ubiquinone exists in crystalline powder at 
room temperature. Although it is highly lipophilic, it has limited solubility in 
lipids. Moreover, the compound has relatively high molecular weight. These 
factors have contributed to the poor and erratic absorption of ubiquinone upon 
oral administration (Miles et a/., 2002; Joshi et a/., 2003). Being a lipophilic 
substance, the absorption of ubiquinone mimics similar pathway to that of fat-
soluble drugs, which involves emulsification with bile salts in the intestines, 
followed by the formation of micelles prior to absorption. Upon absorption from 
the gastrointestinal tract, ubiquinone will be taken up by the chylomicrons. 
According to Greenberg and Frishman (1990), a major portion of the 
exogenous ubiquinone is deposited in the liver and packaged into VLDL 
lipoprotein. 
Various methods of increasing the oral bioavailability of ubiquinone have been 
documented as well as patented. Oily suspension of ubiquinone was found to 
yield better absorption compared to the powdered form (Weis et a/., 1994). 
Formulation of ubiquinone into self-emulsifying preparations has been shown to 
significantly improve the oral bioavailability of ubiquinone compared to the oily 
suspensions and powdered preparations (Chopra eta/., 1998; Wahlqvist eta/., 
1998; Miles eta/., 2002; Molyneux eta/., 2004) 
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1.7 SCOPE OF THE STUDY 
To date, the most successful commercially available ubiquinone formulation, 
with enhanced oral bioavailability, is a self-microemulsifying (SME) formulation 
comprising almost 90% of surfactants according to the patented formula 
(Goldman, 2000). High amounts of surfactants were required to obtain small 
droplet sizes. However, the high amounts of surfactants present in SME 
formulations might cause permeability changes in the intestinal walls and thus 
might not be recommended or safe for long-term oral consumption. There is 
also the issue of safety/toxicity in using high amounts of surfactants. 
Therefore the present study was conducted to investigate the feasibility of using 
minimal amounts of a single surfactant system in the formulation of a SEDDS 
for enhancing the oral absorption of ubiquinone. The study was carried out in 
stages with the following objectives: 
1. to develop a high performance liquid chromatographic method for 
quantification of ubiquinone in plasma matrices; 
2. to formulate a SEDDS comprising a suitable lipidic vehicle and a single 
surfactant with efficient self-emulsifying properties; 
3. to evaluate the in vitro performance of SEDDS based on droplet size 
analysis, physical stability of the resultant emulsion products and chemical 
stability of ubiquinone in the optimised SE formulation; 
4. to evaluate the in vivo performance of an optimised SE formulation of 
ubiquinone in adult male Sprague-Dawley rats; 
5. to evaluate the in vivo performance of an optimised SE formulation of 
ubiquinone in healthy human volunteers. 
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CHAPTER 2 DEVELOPMENT OF A SIMPLE HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHIC METHOD FOR ANALYSIS OF 
UBIQUINONE IN RAT AND HUMAN PLASMA 
2.1 INTRODUCTION 
Various analytical methods using high performance liquid chromatography 
(HPLC) have been reported for quantifying ubiquinone and ubiquinol in plasma, 
erythrocytes, urine and animal tissues. Ubiquinol, the reduced form of 
ubiquinone, is the most common form found in vivo (Kontush eta/., 1997), but it 
can be easily oxidised to ubiquinone not only at room temperature but also at 
-2ooc (Edlund, 1988; Eaton et a/., 2000). Despite its poor stability, it is 
sometimes necessary to determine the ubiquinol levels, since its ratio to the 
total ubiquinone can be used to determine ubiquinone deficiency related 
diseases (Kontush et a/., 1997; Menke et a/., 2000). However, quantification of 
total ubiquinone in plasma or serum is deemed sufficient for determining the 
rate and extent of ubiquinone absorption in bioavailability studies, noting that 
the majority of bioavailability studies on ubiquinone reported in the literature 
were based on quantification of total ubiquinone. 
Karpinska et a/. (1998) described an ultra-violet (UV) spectrophotometric 
method for the quantification of plasma ubiquinone, which was claimed to be 
simpler and faster than methods based on HPLC. The method utilised 
derivatisation spectrophotometry, in which the approach was based on a 
mathematical transformation of the spectral curve obtained. However, 
spectrophotometric methods are generally deemed not specific. Moreover, no 
internal standard could be utilised in the double extraction procedure during 
sample clean-up because such detection method is unable to distinguish the 
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compound of interest from the internal standard, which customarily has a 
similar UV absorbance to that of the compound of interest. 
Various HPLC methods using electrochemical detection (ECD) have also been 
reported in the literature. Lang and Packer (1987) reported such a method with 
sensitivity of approximately 40 ng/ml, being comparable to that achieved using 
HPLC-UV detection (Kommuru eta/., 1998; Mosca eta/., 2002), but no mention 
was made regarding its precision and accuracy. Another method reported by 
Edlund (1988) could produce clean chromatograms and simultaneously 
quantify ubiquinol, ubiquinone and vitamin E. However, the method was not 
validated for precision and accuracy. Grossi et a/. (1992) also reported a 
method that could achieve excellent sensitivity of 5 ng/ml by coupling solid-
phase extraction (SPE) and on-line column sample clean-up using column 
switching system with ECD. Besides being tedious and laborious to perform, 
methods employing ECD in general, often encounter problems of baseline 
stability. 
Quantification of plasma ubiquinone using HPLC methods with UV detection 
has also been reported. Okamoto et a/. (1985) reported a HPLC-UV method, 
which required double sample clean-up involving liquid-liquid extraction 
followed by thin-layer chromatography (TLC). However, its limit of detection 
was only 100 ng/ml, being less sensitive than other HPLC-UV methods. Also, 
the accuracy, precision and recovery of the method were not reported. 
Although an HPLC-UV method by Kommuru et at. (1998) could obtain a 
detection limit of 50 ng/ml, the analytical procedure was lengthy and tedious 
requiring triple extraction of the samples. Moreover, the analysis run time for 
each sample was long, taking up to 30 minutes per sample. 
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More recently, Mosca eta/. (2002) reported a HPLC-UV method, which has a 
good sample clean-up recovery of 97.3%. The method also has a high 
sensitivity of 32 ng/ml, with good precision and accuracy where the coefficient 
of variation and error values were less than 11%. A simple direct 
deproteinisation of the sample was used as the clean-up procedure. The 
setback of this method is that a relatively large volume of 200 J.LI of the 
deproteinised plasma supernatant was required to be injected into the HPLC 
column. This might lead to rapid clogging of the HPLC column resulting in 
shortening of the column life span. Also the relatively long run time of 13.5 
minutes might be impractical, especially when a large number of samples need 
to be analysed, such as those obtained from bioavailability studies. 
Therefore, the aim of this part of the study was to develop a simple, rapid, 
economical and yet specific as well as sufficiently sensitive HPLC method using 
UV detection for the determination of ubiquinone in rat and human plasma. 
According to Edlund (1988), ubiquinone is negligibly found in rat plasma but 
present at significant levels in human plasma. Hence, method validation was 
performed for both human and rat plasma due to the differences in their 
matrices. 
2.2 MATERIALS 
Hexane, 2-propanol (IPA), acetonitrile (ACN) and tetrahydrofuran (THF) of 
either HPLC or analytical reagent (AR) grade were purchased from Mallinckrodt 
(Paris, KY, USA), while methanol of AR grade was acquired from Merck 
(Darmstadt, Germany). Ubiquinone reference standard was obtained from 
European Pharmacopeia, Strasbourg, France. 
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2.3 METHODS 
2.3.1 INSTRUMENTATION 
The HPLC system comprised a Jasco PU-980 pump (Jasco, Tokyo, Japan), a 
Gilson 151 UVNis detector (Gilson, Villiers-Le-Bel, France), a Rheodyne 7125 
sample injector fitted with a 50 J..l.l sample loop (Rheodyne, CA, USA) and a 
Hitachi D-2500 Chromate-integrator (Hitachi, Tokyo, Japan). A Zorbax XDB 
C18 (Palo Alto, CA, USA) column (250 x 4.6 mm i.d., 5 J..l.m), fitted with a 
refillable guard column (Upchurch Scientific, Oak Harbour, WA, USA), was 
used for the chromatographic separation. The mobile phase consisting of IPA, 
ACN and distilled water at a ratio of 76 : 20 : 4 v/v, was delivered at a flow rate 
of 1.2 ml/min. The detection wavelength was set at 275 nm with a sensitivity 
range of 0.001 a.u.f.s. 
2.3.2 SAMPLE PREPARATION 
An aliquot of 100 J..l.l of plasma (obtained from either rat or human) was 
accurately pipetted into a microcentrifuge tube (Eppendorf, Hamburg, 
Germany) and deproteinised using 200 J..l.l of THF. The mixture was mixed 
thoroughly for 1 minute on a vortex-mixer (Thermolyne, Iowa, USA) before 
being centrifuged (Minispin® Plus Eppendorf, Hamburg, Germany) at 12 800 g 
for 10 minutes. Finally, 50 J..l.l of the supernatant obtained was directly injected 
onto the HPLC system. 
2.3.3 STANDARD SOLUTIONS AND CALIBRATION CURVES 
A stock solution of ubiquinone was prepared in IPA at a concentration of 10 
mg/ml. The stock solution was then diluted using mobile phase to yield a 
working solution of 400 J..l.glml of ubiquinone. Calibration curves of ubiquinone in 
plasma at 10000.0, 5000.0, 2500.0, 1250.0, 625.0, 312.5, 156.3 and 78.1 ng/ml 
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were constructed by first spiking 10 ml of pooled blank plasma with 250 J.ll 
aliquot of ubiquinone working solution (to give a plasma concentration of 10 000 
ng/ml), followed by serial dilution with blank plasma to obtain the subsequent 
plasma concentrations. These samples were also used for the recovery, 
precision and accuracy studies of the assay method. 
Further serial dilutions of the working solution (400 JJ.g/ml) with IPA were carried 
out to obtain concentrations of 1 00.0, 50.0, 25.0, 12.5, 6.3, 3.1, 1.6 and 0.8 
J.lg/ml. These were then used to prepare drug solutions for recovery evaluation, 
by accurately spiking 1 0 J.ll of each of these samples into an appropriate 
amount of deproteinised blank plasma (prepared according to the 
deproteinisation procedure as described in section 2.3.2) to obtain similar 
concentrations as the plasma samples. The solutions were then vortex-mixed 
for 10 seconds and centrifuged at 12 800 g for 5 minutes prior to analysis. 
2.3.4 RECOVERY, PRECISION AND ACCURACY 
Plasma samples were quantified using peak height. For human plasma, 
corrections were made for the interference from endogenous ubiquinone by 
subtracting the peak height from the blank plasma used in the preparation of 
the calibration curves. Recovery, within- and between-day precision and 
accuracy of the method were determined at concentrations of 78.1, 156.3, 
625.0, 1250.0, 2500.0, 5000.0 and 10000.0 ng/ml, respectively (using the 
plasma samples prepared in section 2.3.3 above). For within-day accuracy and 
precision, 6 replicates of each concentration were determined in a single day. 
For between-day evaluation, analysis was carried out on one sample of each 
concentration daily over 6 days with a calibration curve constructed on each 
day of analysis. The accuracy was reported as percentage of the measured 
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concentration over that of the theoretical spiked value, whereas the precision 
was denoted using the coefficient variation of the 6 replicates. The absolute 
recovery (n=6) of the sample preparation method was estimated by comparing 
the peak height obtained from the plasma samples with that obtained from 
similar concentrations of the drug spiked in deproteinised blank plasma 
(prepared according to procedure described in section 2.3.3). 
2.4 RESULTS 
Chromatograms obtained with blank rat plasma and rat plasma spiked with 
1250.0 ng/ml of ubiquinone are shown in Figures 2.1 (a) and (b), while Figure 
2.1 (c) illustrates a chromatogram of rat plasma containing 1133.3 ng/ml of 
ubiquinone, obtained 36 hours after oral administration of 400 mg!kg of 
ubiquinone in a self-emulsifying (SE) formulation. The chromatogram of the 
blank rat plasma was clean and devoid of interference from other endogenous 
compounds at the retention time of ubiquinone. 
Figures 2.2 (a) and 2.2 (b) show the chromatograms obtained with blank 
human plasma and human plasma spiked with 1250.0 ng/ml of ubiquinone, 
while the chromatogram of human plasma sample containing 1745.6 ng/ml of 
ubiquinone, obtained 6 hours after oral administration of 180 mg of ubiquinone 
SE formulation is illustrated in Figure 2.2 (c). Unlike the rat plasma samples, 
endogenous plasma ubiquinone was found to be present at 0.6 to 1.0 Jlg/ml in 
the blank human plasma. Therefore, as mentioned earlier, corrections were 
made to accommodate the interference from endogenous ubiquinone in the 
present analysis. 
Calibration curves (n=6), obtained by plotting the peak height of ubiquinone in 
rat plasma versus the plasma concentration of ubiquinone, were linear over the 
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igure 2.1. Chromatograms for the analysis of ubiquinone in (a) bla.nk rat plasma, (b) 
lank rat plasma spiked with 1250.0 ng/ml ubiquinone and (c) rat plasma containing 
133.3 ng/ml of ubiquinone, obtained 36 hours after oral administration of 400 mg/kg of 
Jiquinone in SE formulation (y-axis, attenuation 6; x-axis, chart speed 2.5 mm/min). 
etention time of ubiquinone ::::: 8.4 mins 
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Figure 2.2. Chromatograms for the analysis of ubiquinone in (a) blank human plasma, 
{b) blank human plasma spiked with 1250.0 ng/ml ubiquinone and (c) human plasma 
containing 17 45.6 ng/ml of ubiquinone, obtained 6 hours after oral administration of 
180 mg of ubiquinone SES formulation (y-axis, attenuation 6; x-axis, chart speed 2.5 
mm/min). Retention time of ubiquinone ~ 8. 7 mins 
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